Carlsmed, Inc. (CARL) vs Myriad Genetics, Inc. (MYGN)
A side-by-side comparison of Carlsmed, Inc. and Myriad Genetics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CARL
Carlsmed, Inc.
$14.94HealthcareDelayed quote: Oct 6, 2026, 11:00 AM EDT
MYGN
Myriad Genetics, Inc.
$4.27HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT
Total return — CARL vs MYGN
growth of $100 · dividends reinvested · last 1yCARL +5.5% (+5.5%/yr)MYGN +2.5% (+2.5%/yr)CARL compounded faster over this window
CARL MYGN
CARL vs MYGN: by the numbers
- •CARL is the larger company ($406M vs $403M market cap).
- •Both run net losses; MYGN's is the smaller (-13.96% vs -57.42% net margin).
Metrics side by side
Valuation
| Metric | CARL | MYGN |
|---|---|---|
| P/S ratio | 6.42 | 0.50 |
| P/B ratio | 4.82 | 1.33 |
Profitability
| Metric | CARL | MYGN |
|---|---|---|
| Gross margin | 76.63% | 68.83% |
| Operating margin | -61.09% | -12.22% |
| Net margin | -57.42% | -13.96% |
| ROE | -43.14% | -37.05% |
| ROIC | -36.54% | -19.13% |
Growth (annualized)
| Metric | CARL | MYGN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 9.70% |
| Total return CAGR (5Y) | N/A | -32.02% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.